CA2482637C - New esters of hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions - Google Patents

New esters of hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions Download PDF

Info

Publication number
CA2482637C
CA2482637C CA2482637A CA2482637A CA2482637C CA 2482637 C CA2482637 C CA 2482637C CA 2482637 A CA2482637 A CA 2482637A CA 2482637 A CA2482637 A CA 2482637A CA 2482637 C CA2482637 C CA 2482637C
Authority
CA
Canada
Prior art keywords
formula
denote
hydroxy
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2482637A
Other languages
English (en)
French (fr)
Other versions
CA2482637A1 (en
Inventor
Michael P. Pieper
Gerald Pohl
Georg Speck
Matthias Grauert
Steffen Breitfelder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2482637A1 publication Critical patent/CA2482637A1/en
Application granted granted Critical
Publication of CA2482637C publication Critical patent/CA2482637C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2482637A 2002-04-13 2003-04-11 New esters of hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions Expired - Lifetime CA2482637C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10216339.1 2002-04-13
DE10216339A DE10216339A1 (de) 2002-04-13 2002-04-13 Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
PCT/EP2003/003765 WO2003087096A1 (de) 2002-04-13 2003-04-11 Neue ester hydroxy-substituierter stickstoffheterocyclen als antagonisten des muskarinischen m3 rezeptors, vefahren zu deren herstellung sowie deren verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
CA2482637A1 CA2482637A1 (en) 2003-10-23
CA2482637C true CA2482637C (en) 2011-09-20

Family

ID=28458782

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2482637A Expired - Lifetime CA2482637C (en) 2002-04-13 2003-04-11 New esters of hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions

Country Status (8)

Country Link
EP (1) EP1497288B1 (enExample)
JP (1) JP4589006B2 (enExample)
AT (1) ATE314366T1 (enExample)
AU (1) AU2003222290A1 (enExample)
CA (1) CA2482637C (enExample)
DE (2) DE10216339A1 (enExample)
ES (1) ES2254925T3 (enExample)
WO (1) WO2003087096A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004021921D1 (de) 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
JP2009543860A (ja) 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用
KR101517574B1 (ko) 2007-09-07 2015-05-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 길항제로서 유용한 구아니딘을 함유하는 화합물
AU2009252938B2 (en) 2008-05-27 2012-04-26 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
WO2011094434A2 (en) * 2010-01-28 2011-08-04 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
DK3691620T3 (da) 2017-10-05 2022-10-03 Fulcrum Therapeutics Inc P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives

Also Published As

Publication number Publication date
CA2482637A1 (en) 2003-10-23
JP4589006B2 (ja) 2010-12-01
WO2003087096A1 (de) 2003-10-23
DE50302065D1 (de) 2006-02-02
AU2003222290A1 (en) 2003-10-27
DE10216339A1 (de) 2003-10-23
ATE314366T1 (de) 2006-01-15
JP2005529110A (ja) 2005-09-29
EP1497288B1 (de) 2005-12-28
ES2254925T3 (es) 2006-06-16
EP1497288A1 (de) 2005-01-19

Similar Documents

Publication Publication Date Title
CA2472149C (en) New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments
CA2474874C (en) Anticholinergic agents, method for producing the same and use thereof as medicaments
CA2471578C (en) Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments
US6696462B2 (en) Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
US6790856B2 (en) Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
JP2005516067A6 (ja) 新規フルオレンカルボン酸エステル、その製造方法及び薬物としてのその使用
CA2507110C (en) Carbamic acid esters with an anticholinergic action
US7094788B2 (en) Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
CA2482637C (en) New esters of hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
US7405224B2 (en) Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions
US20030229227A1 (en) New difurylglycolic acid esters, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
CA2476746A1 (en) Difurylglycolic acid tropenol esters used as anticholinesterase drugs
ZA200404366B (en) Novel fluorene carboxylic acid esters methods for the production thereof and use of the same as pharmaceuticals
HK1082376B (en) Fluorene carboxylic acid esters, methods for the production thereof, and use of the same for preparing pharmaceuticals

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230411